Observational studyWorld journal of gastroenterology2015
Human epidermal growth factor receptor 2 expression in mixed gastric carcinoma.
Observational study in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.American journal of clinical pathology · 2016Guideline
- Immune Cell Crisis and Excess Histopathological Features During the Development and Progression ofInternational journal of general medicine · 2025Article
- Assessing clinical pathological characteristics and gene expression patterns associated with hepatoid adenocarcinoma of the stomach.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Article
- Histogenetic insights and genetic landscape of fibromatosis-like undifferentiated gastric carcinoma: a focused study.World journal of surgical oncology · 2024Article
- Histopathological features of glandular atrophy of the lamina propria of the gastric mucosa during its occurrence and development.BMC gastroenterology · 2023Article
- Clinicopathological features and differential diagnosis of gastric pleomorphic giant cell carcinoma.Open life sciences · 2023Article
- Clinicopathological characteristics of signet-ring cell carcinoma derived from gastric fovelar epithelium.Journal of digestive diseases · 2022Article
- Dual block HER2 assessment increased HER2 immunohistochemistry positive rate in resected specimens of gastric cancer: a prospective multicenter clinical trial from China.Diagnostic pathology · 2022Article
- An Exceptionally Rare Primary Epithelioid Rhabdomyosarcomas of the Stomach: A Case Report.Cureus · 2022Article
- Research on the Histological Features and Pathological Types of Gastric Adenocarcinoma With Mucinous Differentiation.Frontiers in medicine · 2022Article
- Clinicopathological features and differential diagnosis of gastrofibromatosis-like undifferentiated carcinoma.The Journal of international medical research · 2020Article
- HER2 Heterogeneity in Personalized Therapy of Gastro-Oesophageal Malignancies: An Overview by Different Methodologies.Journal of personalized medicine · 2020Review
- Significance of Detection of the HER2 Gene and PD-1/PD-L1 in Gastric Cancer.Journal of oncology · 2020Article
- Primary epithelioid rhabdomyosarcoma of the stomach: a case report and review of literature.Diagnostic pathology · 2019Review
- Methods and significance of the combined detection of HER2 gene amplification and chemosensitivity in gastric cancer.Cancer biomarkers : section A of Disease markers · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate human epidermal growth factor receptor 2 (HER2) amplification and protein expression in mixed gastric carcinoma.
methodsFluorescence in situ hybridization and immunohistochemistry were used to detect HER2 amplification and protein expression in 277 cases of mixed gastric carcinoma. Protein staining intensity was rate as 1+, 2+, or 3+.
resultsOf the 277 cases, 114 (41.2%) expressed HER2 protein. HER2 3+ staining was observed in 28/277 (10.1%) cases, 2+ in 37/277 (13.4%) cases, and 1+ in 49/277 (17.7%) cases. A HER2 amplification rate of 17% was detected, of which 25/28 (89.3%) were observed in the HER2 3+ staining group, 17/37 (45.9%) in 2+, and 5/49 (10.2%) in 1+. Of the 47 patients with HER2 amplification who received chemotherapy plus trastuzumab, 22 demonstrated median progression-free and overall survivals of 9.1 mo and 16.7 mo, respectively, which were significantly better than those achieved with chemotherapy alone (5.6 mo and 12.1 mo, respectively) in 19 previously treated patients (Ps < 0.05).
conclusionHER2 detection in mixed gastric carcinoma displays high heterogeneity. Relatively quantitative parameters are needed for assessing the level of HER2 amplification and protein expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.